Investors in Jaguar Health (NASDAQ: JAGX) are experiencing a rough day as the company’s stock takes a hit following the release of results from a Phase 3 clinical trial. The trial focused on the use of crofelemer as a treatment for diarrhea in adult cancer patients with solid tumors receiving targeted therapy. While crofelemer is already FDA-approved for HIV/AIDS patients, the trial failed to meet its primary endpoint for all tumor types except breast and respiratory cancers.
This disappointing news has led to a significant drop in JAGX stock, with shares down 55.2% as of Tuesday afternoon. Heavy trading volume, exceeding the daily average by over 12 million units, indicates that traders are selling off their shares in response to the trial results.
For investors, it’s essential to stay informed about market developments like this one. Keep reading for more updates on today’s stock market news, including updates on AMC Entertainment (NYSE: AMC), Adial Pharmaceuticals (NASDAQ: ADIL), and CrowdStrike (NASDAQ: CRWD).
Analysis Breakdown:
1. Jaguar Health (JAGX) stock is plummeting after disappointing Phase 3 clinical trial results for crofelemer.
2. Crofelemer’s effectiveness was limited to breast and respiratory cancer patients, failing to meet its primary endpoint for other tumor types.
3. Heavy trading volume indicates significant sell-off activity, with shares down 55.2% on Tuesday.
4. Investors should stay informed about market developments to make well-informed decisions about their investments.
Remember, it’s crucial to keep track of market news and trends to protect and grow your investment portfolio. Stay informed and make strategic decisions to navigate the ups and downs of the stock market effectively.